Investigative ophthalmology & visual science · 2019
Subfoveal Choroidal Thickness, Cardiovascular History, and Risk Factors in the Elderly: The Montrachet Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Arnould Louis, Seydou Alassane, Gabrielle Pierre-Henry, Guenancia Charles, Tzourio Christophe, Bourredjem Abderrahmane, El Alami Youssef, Daien Vincent, Binquet Christine, Bron Alain Marie, Creuzot-Garcher Catherine
Аннотация
PURPOSE: To measure subfoveal choroidal thickness (SFCT) in the elderly and to determine the associations among SFCT, cardiovascular history, and the 10-year risk of fatal cardiovascular disease (CVD).
METHODS: We conducted a population-based study, the Montrachet (Maculopathy Optic Nerve, nuTRition neurovAsCular, and HEarT disease) study, in subjects older than 75 years. SFCT was measured with spectral-domain optical coherence tomography (SD-OCT) with enhanced-depth mode imaging. Participants underwent a comprehensive eye examination. The history of CVD, CVD risk factors, and a score-based estimation of their 10-year risk of cardiovascular mortality (Heart Score) were collected.
RESULTS: Overall, 764 participants were retained for analysis. The mean SFCT was 206.4 ± 83.0 μm. The mean age was 81.9 ± 3.6 years. After a multivariable analysis, older age (β = -32.56 μm, P < 0.001) and longer axial length (β = -20.71 μm, P < 0.001) were independently associated with thinner SFCT. SFCT was not significantly associated with sex, cardiovascular history, classical CVD risk factors, or prognostic risk score.
CONCLUSIONS: This study confirms that longer axial length and older age are associated with thinner SFCT. However, SFCT does not appear to be a biomarker for cardiovascular history in this study.
METHODS: We conducted a population-based study, the Montrachet (Maculopathy Optic Nerve, nuTRition neurovAsCular, and HEarT disease) study, in subjects older than 75 years. SFCT was measured with spectral-domain optical coherence tomography (SD-OCT) with enhanced-depth mode imaging. Participants underwent a comprehensive eye examination. The history of CVD, CVD risk factors, and a score-based estimation of their 10-year risk of cardiovascular mortality (Heart Score) were collected.
RESULTS: Overall, 764 participants were retained for analysis. The mean SFCT was 206.4 ± 83.0 μm. The mean age was 81.9 ± 3.6 years. After a multivariable analysis, older age (β = -32.56 μm, P < 0.001) and longer axial length (β = -20.71 μm, P < 0.001) were independently associated with thinner SFCT. SFCT was not significantly associated with sex, cardiovascular history, classical CVD risk factors, or prognostic risk score.
CONCLUSIONS: This study confirms that longer axial length and older age are associated with thinner SFCT. However, SFCT does not appear to be a biomarker for cardiovascular history in this study.